Sep 22, 2025 | Press Releases
CINCINNATI, Sept. 22, 2025 (GLOBE NEWSWIRE) — Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) a commercial stage biotechnology company focused on the research, development and commercialization of innovative solutions for...
Jul 16, 2025 | Press Releases
CINCINNATI, July 16, 2025 — Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) and Ocuvex Therapeutics, Inc. (“Ocuvex”), a privately held biopharmaceutical company focused on the development and commercialization of...
Jun 16, 2025 | Press Releases
CINCINNATI, Ohio, June 16, 2025 — Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s...
Jun 11, 2025 | Press Releases
CINCINNATI, Ohio, June 11, 2025 — Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s...
May 22, 2025 | Press Releases
Cincinnati, OH, May 22, 2025 — Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on May 20, 2025 indicating that the Company’s failure to...
Apr 30, 2025 | Press Releases
Cincinnati, OH, April 30, 2025 — Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from The Nasdaq Capital Market (“Nasdaq”) on April 24, 2025 indicating that the Company’s failure to...